Volume 12 Supplement 1
Melanoma Bridge 2013: Poster and Oral Presentations
Edited by Paolo A Ascierto, Nicola Mozzillo, Francesco M Marincola, Gennaro Cilberto, John M Kirkwood, Giuseppe Masucci, Ignacio Melero, Antoni Ribas and Magdalena Thurin
The conference and publication charges for this supplement were funded by 3P Solution. Abstracts were selected by the Scientific Committee of the conference. Supplement Editor declarations: Ignacio Melero has served as a consultant and/or advisory board member for Bristol-Myers Squibb, Merck Serono and Genentech-Roche. John M Kirkwood has been a consultant for Bristol-Myers Squibb, Merck, GlaxoSmithKline, Novartis, Ziopharm, Celgene and Vical in the past five years. Paolo Ascierto has been a consultant for Bristol-Myers Squibb, Merck Sharp & Dohme, Roche-Genentech, GlaxoSmithKline, Ventana and Novartis. He has received research funds from Bristol-Myers Squibb, Roche-Genentech and Ventana. He has also received honoraria from Bristol-Myers Squibb, Roche-Genentech and GlaxoSmithKline. Antoni Ribas has been a consultant for Amgen, GlaxoSmithKline, Genentech-Roche, Merck, Novartis and Daiichi-Sanko with the honoraria paid to University of California, Los Angeles. He is also a stock holder in Kite Pharma and Flexus Biotherapeutics. Nicola Mozzillo, Francesco M Marincola, Gennaro Cilberto, Giuseppe Masucci and Magdalena Thurin declare that they have no competing interests.
Melanoma Bridge meeting 2013. Go to conference site.
Naples, Italy5-8 December 2013
Annual Journal Metrics
56 days to first decision for reviewed manuscripts only
51 days to first decision for all manuscripts
104 days from submission to acceptance
10 days from acceptance to publication
2,714 Altmetric mentions